Market News

New York: Raymond James Financial (NYSE:RJF) Stock Has Just Had Its Neutral Rating Reiterated by Citigroup. Shares now Have a $85 Target

New York: Raymond James Financial (NYSE:RJF) Stock Has Just Had Its Neutral Rating Reiterated by Citigroup. Shares now Have a $85 Target

Investors sentiment decreased to 0.93 in Q2 2018. Its down 0.05, from 0.98 in 2018Q1. It dropped, as 32 investors sold Raymond James Financial, Inc. shares while 162 reduced holdings. 50 funds opened positions while 131 raised stakes. 101.06 million shares or 1.17% more from 99.89 million shares in 2018Q1 […]

Reaffirmed: Agree Realty (NYSE:ADC) Outperform Rating Kept by Analysts at Raymond James; $68 Target in Place

Reaffirmed: Agree Realty (NYSE:ADC) Outperform Rating Kept by Analysts at Raymond James; $68 Target in Place

Investors sentiment decreased to 1.35 in 2018 Q2. Its down 0.62, from 1.97 in 2018Q1. It turned negative, as 19 investors sold Agree Realty Corporation shares while 56 reduced holdings. 37 funds opened positions while 64 raised stakes. 29.29 million shares or 1.92% more from 28.74 million shares in 2018Q1 […]

Analysts at Nomura Maintain their Past ‘”Neutral”’ rating on Shares Signet Jewelers (NYSE:SIG), Set a $42 Target Price

Analysts at Nomura Maintain their Past ‘”Neutral”’ rating on Shares Signet Jewelers (NYSE:SIG), Set a $42 Target Price

Investors sentiment decreased to 0.87 in 2018 Q2. Its down 0.14, from 1.01 in 2018Q1. It turned negative, as 48 investors sold Signet Jewelers Limited shares while 87 reduced holdings. 52 funds opened positions while 65 raised stakes. 58.24 million shares or 6.40% more from 54.73 million shares in 2018Q1 […]

How Will Imprimis Pharmaceuticals (NASDAQ:IMMY) Stock React To New Rating Coverage byLake Street?

How Will Imprimis Pharmaceuticals (NASDAQ:IMMY) Stock React To New Rating Coverage byLake Street?

Investors sentiment increased to 1.8 in 2018 Q2. Its up 0.92, from 0.88 in 2018Q1. It increased, as 3 investors sold Imprimis Pharmaceuticals, Inc. shares while 2 reduced holdings. 3 funds opened positions while 6 raised stakes. 1.64 million shares or 32.47% more from 1.24 million shares in 2018Q1 were […]

20.07 % to Target, Citigroup Maintains ‘Neutral’ Rating on Audentes Therapeutics (BOLD) Shares Today

20.07 % to Target, Citigroup Maintains ‘Neutral’ Rating on Audentes Therapeutics (BOLD) Shares Today

Audentes Therapeutics (BOLD) Rating Reaffirmed In a note sent to investors and clients this morning, Citigroup reiterated their Neutral rating on Audentes Therapeutics (BOLD) shares. The price target gives a possible upside of 20.07 % from firm’s close price. Audentes Therapeutics, Inc. (NASDAQ:BOLD) Ratings Coverage Among 9 analysts covering Audentes […]

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Coverage Initiated By Canaccord Genuity with a $23 Price

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Coverage Initiated By Canaccord Genuity with a $23 Price

Investors sentiment increased to 1.22 in Q2 2018. Its up 0.33, from 0.89 in 2018Q1. It improved, as 31 investors sold ACADIA Pharmaceuticals Inc. shares while 43 reduced holdings. 35 funds opened positions while 55 raised stakes. 114.30 million shares or 4.25% less from 119.37 million shares in 2018Q1 were […]

Welltower (WELL) Is Now Covered By Scotiabank. What can We Expect?

Welltower (WELL) Is Now Covered By Scotiabank. What can We Expect?

Why Has Scotiabank Given Welltower (WELL) a $74 Price Target In analysts note issued to clients today, Scotiabank analysts has initiated Welltower (WELL) coverage with Sector Perform rating, and a $74 TP. Welltower Inc. (NYSE:WELL) Ratings Coverage Among 2 analysts covering Welltower (WELL), 1 have Buy rating, 0 Sell and […]

Should Anglogold Ashanti (NYSE:AU) Shares Be Watched After BMO Capital Initiates Coverage?

Should Anglogold Ashanti (NYSE:AU) Shares Be Watched After BMO Capital Initiates Coverage?

Why Has BMO Capital Given Anglogold Ashanti (NYSE:AU) a $11 Price Target Expert analysts at BMO Capital placed a key Market Perform rating for Anglogold Ashanti (NYSE:AU). The firm initiated coverage in a research report sent to investors and clients on 10 December. The target price indicates downside of -0.90 […]